Smart pen and sensor combo aims to simplify diabetes management
NCT ID NCT06645834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a smart system that combines a Bluetooth-enabled insulin pen with a continuous glucose monitor to help people with type 1 diabetes manage their blood sugar. 179 participants used either the smart system or standard insulin injections and glucose monitoring for 6 months. The goal was to see if the smart system helped them stay in their target blood sugar range more often.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Smart MDI System (InPen smart insulin pen and Simplera continuous glucose monitor)
What this could lead to
If successful, this smart system could help people with type 1 diabetes spend more time in their target blood sugar range, making daily diabetes management easier and safer.
What could go wrong
This is a completed study comparing a device to standard care, so results are already known. However, the device may not work for everyone, and benefits might be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Spedali Civili Brescia
Brescia, Italy
-
Antwerp University Hospital
Antwerp, Belgium
-
CHRU de Brest service diabetologie endocrinologie
Brest, France
-
CHU Liege
Liège, Belgium
-
CHU Nimes
Nîmes, France
-
Center for DIABeCare, Hospices Civils de Lyon
Lyon, France
-
General University Hospital
Prague, Czechia
-
Hannoversche Kinderheilanstalt
Hanover, Germany
-
Hogsbo Narsjukhus
Västra Frölunda, Sweden
-
Hospital Rangueil
Toulouse, France
-
Hospital Universitaire Bruxelles Erasme
Brussels, Belgium
-
IKEM
Prague, Czechia
-
MVZ Stoffwechselmedizin Leipzig
Leipzig, Germany
-
Sahlgrenska University Hospital
Gothenburg, Sweden
-
UZ Leuven
Leuven, Belgium
-
Uddevalla Hospital
Uddevalla, Sweden
-
University of Bari Aldo Moro
Bari, Italy
-
Zentrum fur digitale Diabetologie Hamburg
Hamburg, Germany